These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33430642)

  • 21. Migraine and reduced work performance: a population-based diary study.
    Von Korff M; Stewart WF; Simon DJ; Lipton RB
    Neurology; 1998 Jun; 50(6):1741-5. PubMed ID: 9633720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study.
    Tepper SJ; Dahlöf CG; Dowson A; Newman L; Mansbach H; Jones M; Pham B; Webster C; Salonen R
    Headache; 2004 Oct; 44(9):856-64. PubMed ID: 15447694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telemedicine as a tool for dietary intervention in NAFLD-HIV patients during the COVID-19 lockdown: A randomized controlled trial.
    Policarpo S; Machado MV; Cortez-Pinto H
    Clin Nutr ESPEN; 2021 Jun; 43():329-334. PubMed ID: 34024536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study.
    Seng EK; Robbins MS; Nicholson RA
    Cephalalgia; 2017 Sep; 37(10):955-964. PubMed ID: 27489178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 3-month analysis of disability, quality of life, and disease course in patients with migraine.
    Raggi A; Leonardi M; Bussone G; D'Amico D
    Headache; 2013 Feb; 53(2):297-309. PubMed ID: 23094760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway.
    Kristoffersen ES; Faiz KW; Sandset EC; Storstein AM; Stefansen S; Winsvold BS; Hansen JM
    J Headache Pain; 2020 Oct; 21(1):128. PubMed ID: 33121445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 lockdown impact on common general surgical acute presentations to a regional centre in New Zealand.
    Boyle LI; Boyle A; Jay S; Marnewick J
    N Z Med J; 2020 Nov; 133(1525):96-105. PubMed ID: 33223552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Navigating migraine care through the COVID-19 pandemic: an update.
    Angus-Leppan H; Guiloff AE; Benson K; Guiloff RJ
    J Neurol; 2021 Nov; 268(11):4388-4395. PubMed ID: 34002281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability.
    Lipton RB; Manack Adams A; Buse DC; Fanning KM; Reed ML
    Headache; 2016 Sep; 56(8):1280-9. PubMed ID: 27349336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of COVID-19 pandemic lockdown on occupational therapy practice and use of telerehabilitation - A cross sectional study.
    Ganesan B; Fong KNK; Meena SK; Prasad P; Tong RKY
    Eur Rev Med Pharmacol Sci; 2021 May; 25(9):3614-3622. PubMed ID: 34002837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence to Biobehavioral Recommendations in Pediatric Migraine as Measured by Electronic Monitoring: The Adherence in Migraine (AIM) Study.
    Kroon Van Diest AM; Ramsey R; Aylward B; Kroner JW; Sullivan SM; Nause K; Allen JR; Chamberlin LA; Slater S; Hommel K; LeCates SL; Kabbouche MA; O'Brien HL; Kacperski J; Hershey AD; Powers SW
    Headache; 2016 Jul; 56(7):1137-46. PubMed ID: 27167502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Migraine Symptoms Improvement During the COVID-19 Lockdown in a Cohort of Children and Adolescents.
    Dallavalle G; Pezzotti E; Provenzi L; Toni F; Carpani A; Borgatti R
    Front Neurol; 2020; 11():579047. PubMed ID: 33133010
    [No Abstract]   [Full Text] [Related]  

  • 34. Mental health presentations to Christchurch Hospital Emergency Department during COVID-19 lockdown.
    Joyce LR; Richardson SK; McCombie A; Hamilton GJ; Ardagh MW
    Emerg Med Australas; 2021 Apr; 33(2):324-330. PubMed ID: 33078509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
    Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB
    J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hospitalizations for Stroke in France During the COVID-19 Pandemic Before, During, and After the National Lockdown.
    Mariet AS; Giroud M; Benzenine E; Cottenet J; Roussot A; Aho-Glélé LS; Tubert-Bitter P; Béjot Y; Quantin C
    Stroke; 2021 Apr; 52(4):1362-1369. PubMed ID: 33626900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attitudes about COVID-19 Lockdown among General Population, France, March 2020.
    Peretti-Watel P; Seror V; Cortaredona S; Launay O; Raude J; Verger P; Beck F; Legleye S; L'Haridon O; Ward J; ; Longitudinale E; ;
    Emerg Infect Dis; 2021 Jan; 27(1):301-3. PubMed ID: 33183493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is Lockdown Effective in Limiting SARS-CoV-2 Epidemic Progression?-a Cross-Country Comparative Evaluation Using Epidemiokinetic Tools.
    Mégarbane B; Bourasset F; Scherrmann JM
    J Gen Intern Med; 2021 Mar; 36(3):746-752. PubMed ID: 33442818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Headache diary in the diagnosis of childhood migraine.
    Metsähonkala L; Sillanpää M; Tuominen J
    Headache; 1997 Apr; 37(4):240-4. PubMed ID: 9150620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.